IU Health
Seyed H. Sayar, MD - Hematology - Oncology

Seyed H. Sayar, MD

IU Health

Hematology - Oncology

4.8 out of 5 stars (399 ratings)
Accepting New Patients
Schedule an Appointment

Already a Patient? Connect on My IU Health

  • Biography
  • Locations
  • Specialties & Details
  • Ratings & Reviews
  • Clinical Trials
  • Related Stories
Biography

Dr. Seyed H. Sayar specializes in Cancer Treatment for IUSCC Hematology Clinic. Dr. Sayar earned his medical degree at Tehran University. He then completed an internship and residency at the University of Arizona Medical Center and a fellowship at the University of New Mexico.

Dr. Sayar currently has a rating of 4.8 stars out of 5 with over 400 ratings. Patients say that he is relatable, empathetic, and intelligent. In a recent five-star review, a patient remarked: "Very caring doctor and interested in the care of his patients."

Dr. Sayar's primary location is IUSCC Hematology Clinic, 1030 West Michigan St, Indianapolis, IN 46202. He also sees patients at offices in Tipton and Avon. In addition to English, he speaks Farsi and Persian.

Locations
Specialties & Details

Specialties:

Hematology - Oncology

Conditions & Treatments:

Leukemia, Myelodysplastic Syndromes (MDS)

Additional Languages:

Farsi, Persian

Education

School of Medicine:

Tehran University, Tehran, Iran

Internship:

University of Arizona Medical Center, Tucson, AZ

Residency:

University of Arizona Medical Center, Tucson, AZ

Fellowship:

University of New Mexico

Hospitals & Affiliations

Hospital Privileges:

IU Health Methodist/IU Health University, IU Health North, IU Health Tipton, IU Health West

Physician Group:

IU Health Physicians

Research

Research Publications
* Information provided by PubMed
Ratings & Reviews
Clinical Trials

Explore the ongoing clinical trials this provider is involved in and learn about the eligibility requirements for each one. Search the clinical trial directory to find additional clinical trials.

A Phase III International Randomized Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

View Details
Related Stories
Read More